SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 19 of 21
Word Count: 1456
Character Count: 9459

Document Content:

declared which materially adversely impacts the United States securities markets; (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your reasonable judgment, make it inadvisable to proceed with the delivery of the Firm Shares (or Option Shares, as the case may be); (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative shall have become aware after the date hereof of a Material Adverse Change or an adverse material change in general market conditions as in the Representative’s reasonable judgment would make it impracticable to proceed with the offering, sale and/or delivery of the Public Shares or to enforce contracts made by the Underwriters for the sale of the Public Shares.

The
Company may terminate this Agreement for cause at any time. For purposes of this Agreement, “termination for cause” means
a termination of this Agreement with respect to the Representative, after reasonable notice by the Company, as a result of (i) the material
failure of the Representative to provide the services in connection with the Offering contemplated in this Agreement, provided that such
failure to provide such services is not a result of market, economic or political conditions, the Company’s condition (financial
or otherwise), any failure by the Company to perform its obligations hereunder or under the securities laws, or any other circumstances
outside the Representative’s control, or (ii) fraud, gross negligence or willful misconduct by the Representative.

Notwithstanding
anything to the contrary herein, if the Company determines in its reasonable good faith judgment to terminate for cause with respect
to the Representative (which shall include the material failure of the Underwriters to provide underwriting services, as provided in
FINRA Rule 5110(g)(5)(B)), the Company shall have no obligation to pay any Future Financing Fees under Section 7.4 of this Agreement.

Expenses. Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant
to Section 6 above, in the event that this Agreement shall expire or be terminated for any reason whatsoever, within the time specified
herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative, within fifteen
(15) calendar days of receipt by the Company, their actual and accountable out-of-pocket and documented expenses related to the transactions
contemplated herein then due and payable (including the fees and disbursements of Representative Counsel), subject to the maximum amount
set forth in Section 3.10. Notwithstanding the foregoing, any portion of the Retainer received by the Representative will be reimbursed
to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).

Survival of Indemnification. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any
termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in
full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this
Agreement or any part hereof.

Representations, Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Shares, the Representative’s
Warrants and/or the Representative Warrant Shares.

Miscellaneous.

Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed
(registered or certified mail, return receipt requested), personally delivered or sent by electronic transmission and confirmed and shall
be deemed given when so delivered or emailed and confirmed (which may be by email) or if mailed, two (2) days after such mailing.

to the Representative:

The
Benchmark Company, LLC

East 58th Street, 17th Floor

New
York, NY 10155

Attention:	Michael
Jacobs

Email:	mjacobs@benchmarkcompany.com

with
a copy (which shall not constitute notice) to:

McGuireWoods
LLP

Avenue of the Americas, 20 th Floor

New
York, NY 10020

Attention:	Stephen
Older, Esq.

Email:	SOlder@mcguirewoods.com

to the Company:

BioVentrix,
Inc.

Forbes Blvd., Suite 125

Mansfield,

Attention:	David
Richmond

Email:	dave@Richmondbrothers.com

with
a copy (which shall not constitute notice) to:

Ellenoff
Grossman & Schole LLP

Avenue of the Americas

New
York, NY 10105

Attention:	Lawrence
A. Rosenbloom, Esq.

Steven
Mermelstein, Esq.

Email:	lrosenbloom@egsllp.com

smermelstein@egsllp.com

Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Agreement.

Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto.

Entire Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding
anything to the contrary set forth herein, it is understood and agreed by the parties hereto that the terms and conditions of that certain
engagement letter between the Company and The Benchmark Company, LLC dated August 5, 2024, as amended, are superseded by this Agreement.

Binding Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal
representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim
under or in respect of or by virtue of this Agreement or any provisions herein contained. The term “successors and assigns”
shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.

Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably
submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State
Tech. §§ 301-309), as amended from time to time, or other applicable law will be deemed original signatures for purposes of
this Agreement. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and
sufficient delivery thereof.